Xenetic Biosciences Return On Equity vs. Return On Asset
| XBIO Stock | USD 4.11 0.10 2.49% |
Return On Equity | First Reported 2010-12-31 | Previous Quarter (0.42) | Current Value (0.44) | Quarterly Volatility 0.83288344 |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.77 | 0.89 |
|
|
For Xenetic Biosciences profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Xenetic Biosciences to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Xenetic Biosciences utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Xenetic Biosciences's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Xenetic Biosciences over time as well as its relative position and ranking within its peers.
Xenetic |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Xenetic Biosciences. If investors know Xenetic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Xenetic Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.66) | Revenue Per Share 1.638 | Quarterly Revenue Growth 0.116 | Return On Assets (0.29) | Return On Equity (0.49) |
The market value of Xenetic Biosciences is measured differently than its book value, which is the value of Xenetic that is recorded on the company's balance sheet. Investors also form their own opinion of Xenetic Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Xenetic Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Xenetic Biosciences' market value can be influenced by many factors that don't directly affect Xenetic Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Xenetic Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Xenetic Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Xenetic Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Xenetic Biosciences Return On Asset vs. Return On Equity Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Xenetic Biosciences's current stock value. Our valuation model uses many indicators to compare Xenetic Biosciences value to that of its competitors to determine the firm's financial worth. Xenetic Biosciences is rated second in return on equity category among its peers. It is rated fourth in return on asset category among its peers . At this time, Xenetic Biosciences' Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Xenetic Biosciences' earnings, one of the primary drivers of an investment's value.Xenetic Return On Asset vs. Return On Equity
Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Xenetic Biosciences |
| = | -0.49 |
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Xenetic Biosciences |
| = | -0.29 |
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
Xenetic Return On Asset Comparison
Xenetic Biosciences is currently under evaluation in return on asset category among its peers.
Xenetic Biosciences Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Xenetic Biosciences, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Xenetic Biosciences will eventually generate negative long term returns. The profitability progress is the general direction of Xenetic Biosciences' change in net profit over the period of time. It can combine multiple indicators of Xenetic Biosciences, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 228.4 K | 311.7 K | |
| Operating Income | -4.5 M | -4.7 M | |
| Income Before Tax | -4.1 M | -4.3 M | |
| Total Other Income Expense Net | 381.1 K | 400.2 K | |
| Net Loss | -4.1 M | -4.3 M | |
| Income Tax Expense | 28.2 K | 26.8 K | |
| Net Loss | -4.4 M | -4.7 M | |
| Non Operating Income Net Other | (565.80) | (594.09) | |
| Net Loss | -6.5 M | -6.8 M | |
| Net Interest Income | 351.8 K | 369.4 K | |
| Interest Income | 351.8 K | 369.4 K | |
| Change To Netincome | 369.4 K | 350.9 K | |
| Net Loss | (2.71) | (2.84) | |
| Income Quality | 1.00 | 1.04 | |
| Net Income Per E B T | 1.12 | 1.10 |
Xenetic Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Xenetic Biosciences. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Xenetic Biosciences position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Xenetic Biosciences' important profitability drivers and their relationship over time.
Use Xenetic Biosciences in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Xenetic Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Xenetic Biosciences will appreciate offsetting losses from the drop in the long position's value.Xenetic Biosciences Pair Trading
Xenetic Biosciences Pair Trading Analysis
The ability to find closely correlated positions to Xenetic Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Xenetic Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Xenetic Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Xenetic Biosciences to buy it.
The correlation of Xenetic Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Xenetic Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Xenetic Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Xenetic Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Xenetic Biosciences position
In addition to having Xenetic Biosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Russia On Wall Street Thematic Idea Now
Russia On Wall Street
Cross-sector and cross-instrument bundle of publicly traded Russian entities that are expected to be listed on USA exchanges or over the counter. The Russia On Wall Street theme has 23 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Russia On Wall Street Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Your Current Watchlist. To learn how to invest in Xenetic Stock, please use our How to Invest in Xenetic Biosciences guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
To fully project Xenetic Biosciences' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Xenetic Biosciences at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Xenetic Biosciences' income statement, its balance sheet, and the statement of cash flows.